Clinical relevance of statins: Their role in secondary prevention

Atherosclerosis Supplements

Volumn 2, Issue 1, 2001, Pages 21-25

  Tonkin, Andrew M ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b NATIONAL HEART FOUNDATION OF AUSTRALIA   (Australia)

Author keywords

4S; CARE; LIPID; WOSCOPS

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PLACEBO; PRAVASTATIN; SIMVASTATIN; HYPOCHOLESTEROLEMIC AGENT;

AGE DISTRIBUTION; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY BYPASS SURGERY; CORONARY RISK; DATA BASE; DIABETES MELLITUS; HEART MUSCLE ISCHEMIA; HIGH RISK POPULATION; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; MORBIDITY; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK REDUCTION; SECONDARY PREVENTION; SEX DIFFERENCE; STROKE; UNSTABLE ANGINA PECTORIS; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; FEMALE; MALE; REVIEW; RISK FACTOR;

ANTICHOLESTEREMIC AGENTS; CEREBROVASCULAR ACCIDENT; CORONARY DISEASE; FEMALE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS;

EID: 0035258458     PISSN: 15675688     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5688(00)00006-4     Document Type: Conference Paper

References (10)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383-1389.
2. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New Engl. J. Med. 335:1996;1001-1009.
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New Engl. J. Med. 339:1998;1349-1357.
4. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New Engl. J. Med. 333:1995;1301-1307.
5. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. J. Am. Med. Assoc. 279:1998;1615-1622.
6. Kjekshus J., Pedersen T.R. Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S). Am. J. Cardiol. 76:1995;64C-68C.
7. Sacks F.M., Braunwald E., Simes R.J., et al. Pretreatment lipid concentrations and coronary event reduction with pravastatin: the Prava-3 pooling project. Circulation. 100:(Suppl. I):1999;1-739. Abstract.
8. Thompson PL. Clinical relevance of statins: instituting treatment early in acute coronary syndrome patients. Atherosclerosis 2000;149, this supplement.
9. Braunwald E. Changing the practice of cardiovascular medicine. Atherosclerosis 2000;149, this supplement.
10. Data on file. Bristol-Myers Squibb.